The Technical Analyst
NeuroSense Therapeutics [NRSN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
NeuroSense Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.38% $1.230
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 21.32 mill |
| EPS: | -0.830 |
| P/E: | -1.480 |
| Earnings Date: | May 25, 2024 |
| SharesOutstanding: | 17.33 mill |
| Avg Daily Volume: | 0.314 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.480 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.25x |
| Company: PE -1.480 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.186 (-84.87%) $-1.044 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.008 - 1.472 ( +/- 18.71%) |
| ATR Model: 14 days |
Forecast:
16:00 - $1.230
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.230
Forecast 2: 16:00 - $1.230
Forecast 3: 16:00 - $1.230
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.230 (-2.38% ) |
| Volume | 0.0423 mill |
| Avg. Vol. | 0.314 mill |
| % of Avg. Vol | 13.45 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NRSN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:26 | buy | $1.300 | N/A | Active |
|---|
NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Latest Press Releases
2024-04-22 08:30:00 - Press Release
Neurosense And Genetika+ Initiate Precision Medicine Collaboration Beginning With Ongoing Phase 2 Clinical Trial In Alzheimer's Disease
Cambridge, mass. , april 22, 2024 /prnewswire/ -- neurosense therapeutics ltd.
2024-04-18 08:30:00 - Press Release
Neurosense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation At The American Academy Of Neurology Annual Meeting
Presentation by massachusetts general chair of neurology merit cudkowicz, md, shows both positive clinical effects and consistent trend toward impact on neurofilament biomarker levels cambridge, mass. , april 18, 2024 /prnewswire/ -- neurosense therapeutics ltd.
2024-04-12 08:30:00 - Press Release
Neurosense To Present Paradigm Data At The American Academy Of Neurology Annual Meeting April 16, 2024
Emerging science (late-breaker equivalent) abstract to be presented at 5:30pm local time highlights phase 2 paradigm outcomes cambridge, mass. , april 12, 2024 /prnewswire/ -- neurosense therapeutics ltd.
2024-04-10 19:16:00 - Press Release
Neurosense Announces Pricing Of $4.5 Million Registered Direct Offering And Concurrent Private Placement
Cambridge, mass. , april 10, 2024 /prnewswire/ -- neurosense therapeutics ltd.
2024-04-09 08:30:00 - Press Release
Neurosense Collaborates With Lonza To Identify Exosome-based Biomarkers, In Order To Advance Neurodegenerative Disease Treatments And Diagnostics
Neurosense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field lonza to develop, optimize, and qualify a method utilizing neuron-derived exosomes ("ndes"), set to be integrated into the clinical development program of primec by neurosense lonza's dev-on-demand solution to enable neurosense to access lonza's process development with rapid initiation, execution, and delivery of work basel, switzerland and cambridge, mass. , april 9, 2024 /prnewswire/ -- lonza (six: lonn), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and neurosense therapeutics ltd.
Latest News
2024-04-12 08:30:00 - PRNewsWire
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass. , April 12, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
2023-11-09 09:00:00 - PRNewsWire
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass. , Nov. 9, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
2023-10-06 18:51:15 - Seeking Alpha
NeuroSense: A Hold Ahead Of Phase 2b ALS Data
NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the company's most pivotal event since its IPO at the end of 2021. The company is also targeting Alzheimer's and Parkinson's with the same drug candidate under different names.
2023-03-23 09:05:00 - PRNewsWire
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept AD study is expected to commence in H1 2023 CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
2023-02-08 09:38:45 - PennyStocks
Penny Stocks To Buy Now? 5 To Watch After News This Week
Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?
2023-01-20 06:00:00 - PennyStocks
3 Ways to Make Money With Penny Stocks Right Now
Use these tips for making money with penny stocks right now The post 3 Ways to Make Money With Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-19 11:28:08 - InvestorPlace
Why Is NeuroSense (NRSN) Stock Up 98% Today?
NeuroSense (NASDAQ: NRSN ) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease ( AD ). The clinical trial covers the use of NeuroSense's combination platform therapy for the treatment of AD.
2022-10-27 08:50:00 - PRNewsWire
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
2022-09-28 10:56:01 - PennyStocks
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
Penny stocks to buy [or avoid] after Biogen Alzheimer's news. The post 4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-21 08:51:00 - PRNewsWire
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Biomarker data to be presented provide indication of PrimeC's efficacy in ALS Phase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarks Topline results expected H1 2023 CAMBRIDGE, Mass. , Sept. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.